Overview
QPS is a global contract research organization focused on bioanalytics and clinical trials, established in 1995. It supports drug discovery, preclinical, and clinical development for pharmaceutical and biotech clients through customized research services and regulatory liaison with agencies and ethics committees. The company operates by delivering GLP and GCP-compliant services and charging fees for tailored projects that meet each client’s study requirements. QPS differentiates itself through operational agility, extensive international drug development experience, and a collaborative team approach that partners with clients to achieve study goals. Its main objective is to help clients accelerate the development and approval of new drugs and therapies.
Work here?Claim your company
Simplify's take
What believers are saying
- QPS upgraded Netherlands ICP-MS systems in August 2026, signaling continued capital investment.
- Oracle Argus launched in January 2026, strengthening safety case management and regulatory reporting.
- QPS's 30-year anniversary and 700-site network support cross-selling into bioanalysis and clinical work.
What critics are saying
- IQVIA, ICON, and Fortrea outscale QPS and win global multi-country Phase III budgets.
- Sponsors are consolidating vendors; QPS risks becoming a niche subcontractor by 2027.
- If clinical-trial demand softens, QPS's smaller footprint and fixed labs pressure margins immediately.
What makes QPS unique
- QPS built a 1,200-plus employee CRO around bioanalysis and Phase I–IV trials since 1995.
- QPS runs nine turnkey facilities across six regions, spanning the US, Europe, Asia.
- QPS combines pharmacovigilance, regulatory affairs, and bioanalysis under one governance framework in 2026.
Help us improve and share your feedback! Did you find this helpful?